Retrophin Receives European Orphan Drug Designation for RE-024 for the Treatment of Pantothenate Kinase-Associated Neurodegeneration
February 24, 2016 08:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the European Commission has granted orphan drug designation to RE-024, the Company’s novel...
Retrophin to Present at the Cowen and Company 36th Annual Health Care Conference
February 23, 2016 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Cowen and Company 36th Annual...
Retrophin to Report Fourth Quarter and Full Year 2015 Financial Results
February 11, 2016 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016 after...
Statement on Imprimis Pharmaceuticals’ Announcement Regarding Thiola®
February 10, 2016 13:28 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) has issued the following statement in response to Imprimis Pharmaceuticals’ announcement of its intention to make a...
Retrophin to Present at the Leerink Partners 5th Annual Global Healthcare Conference
January 27, 2016 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer, will present at the Leerink Partners 5th Annual...
Retrophin Announces Preliminary Full-Year 2015 Revenue of Approximately $99.9 Million
January 11, 2016 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the...
Retrophin Statement on Indictment of Martin Shkreli
December 17, 2015 14:52 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Retrophin has issued the following statement: A new chapter for Retrophin began the day the company replaced Martin Shkreli more than a year ago—and...
Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
November 16, 2015 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the European Commission (EC) has granted sparsentan orphan drug designation for the treatment of...
Retrophin Announces Research Collaboration With the Grace Wilsey Foundation and the Warren Family Research Center for Drug Discovery and Development at the University of Notre Dame
November 05, 2015 08:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced a research collaboration with the Grace Wilsey Foundation and the Warren Family Research Center for Drug...
Retrophin Reports Third Quarter 2015 Financial Results
November 03, 2015 16:05 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2015 financial results. Net product sales for the third quarter 2015 were $28.0...